EP1694315A4 - Glycopegylated factor ix - Google Patents
Glycopegylated factor ixInfo
- Publication number
- EP1694315A4 EP1694315A4 EP04813394A EP04813394A EP1694315A4 EP 1694315 A4 EP1694315 A4 EP 1694315A4 EP 04813394 A EP04813394 A EP 04813394A EP 04813394 A EP04813394 A EP 04813394A EP 1694315 A4 EP1694315 A4 EP 1694315A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- glycopegylated factor
- glycopegylated
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52708903P | 2003-12-03 | 2003-12-03 | |
US53938704P | 2004-01-26 | 2004-01-26 | |
US59274404P | 2004-07-29 | 2004-07-29 | |
US61451804P | 2004-09-29 | 2004-09-29 | |
US62338704P | 2004-10-29 | 2004-10-29 | |
PCT/US2004/041070 WO2005055950A2 (en) | 2003-12-03 | 2004-12-03 | Glycopegylated factor ix |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1694315A2 EP1694315A2 (en) | 2006-08-30 |
EP1694315A4 true EP1694315A4 (en) | 2009-10-28 |
Family
ID=34682416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04813394A Withdrawn EP1694315A4 (en) | 2003-12-03 | 2004-12-03 | Glycopegylated factor ix |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1694315A4 (en) |
JP (1) | JP4738346B2 (en) |
KR (1) | KR101209111B1 (en) |
AU (1) | AU2004296860B2 (en) |
BR (1) | BRPI0417341A (en) |
CA (1) | CA2549413A1 (en) |
IL (1) | IL175661A0 (en) |
MX (1) | MXPA06006023A (en) |
NZ (1) | NZ546733A (en) |
WO (1) | WO2005055950A2 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
CA2552892C (en) | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
AU2014280936B2 (en) * | 2004-06-30 | 2016-12-15 | Nektar Therapeutics | Polymer-factor ix moiety conjugates |
JP2008505119A (en) | 2004-06-30 | 2008-02-21 | ネクター セラピューティクス アラバマ,コーポレイション | Macromolecule-Factor IX Conjugate |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
CN102719508A (en) * | 2005-08-19 | 2012-10-10 | 诺和诺德公司 | Glycopegylated factor VII and factor VIIA |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
CN101516388B (en) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | Glycosylation of peptides via O-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
CA2665480C (en) * | 2006-10-04 | 2019-11-12 | Shawn Defrees | Glycerol linked pegylated sugars and glycopeptides |
JP5876208B2 (en) | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Factor VIIa- (poly) sialic acid conjugate with extended in vivo half-life |
DK2144923T3 (en) | 2007-04-03 | 2013-05-13 | Biogenerix Ag | METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF |
CA3090908A1 (en) * | 2007-04-26 | 2008-11-06 | Aptevo Biotherapeutics Llc | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
ES2551123T3 (en) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Improved process for the production of nucleotide sugars |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
JP5613876B2 (en) * | 2007-10-15 | 2014-10-29 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Human factor IX variants with extended half-life |
US20090176708A1 (en) * | 2007-12-27 | 2009-07-09 | Peter Turecek | Chemically modified factor ix |
CN101965200B (en) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | Conjugated factor VIII molecules |
JP2011517951A (en) * | 2008-04-16 | 2011-06-23 | バイエル・ヘルスケア・エルエルシー | Modified factor IX polypeptides and their use |
EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
ES2856055T3 (en) | 2009-07-27 | 2021-09-27 | Baxalta GmbH | Glycopolysialylation of proteins other than blood clotting proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
DK2459224T3 (en) | 2009-07-27 | 2016-07-25 | Baxalta GmbH | Blodstørkningsproteinkonjugater |
CN102573890A (en) * | 2009-07-31 | 2012-07-11 | 拜耳医药保健有限公司 | Modified factor ix polypeptides and uses thereof |
US8697844B2 (en) | 2009-11-24 | 2014-04-15 | Novo Nordisk A/S | Method of purifying pegylated proteins |
AU2011274414B2 (en) | 2010-07-09 | 2016-10-06 | Bioverativ Therapeutics Inc. | Factor IX polypeptides and methods of use thereof |
PL2654794T3 (en) | 2010-12-22 | 2020-07-27 | Baxalta GmbH | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
TW201519900A (en) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | Compositions and methods for inducing immune tolerance to coagulation factor proteins |
KR20210141608A (en) | 2019-03-19 | 2021-11-23 | 체에스엘 베링 렝나우 아게 | Factor IX variants and their use in therapy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (en) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
EP1260582A1 (en) * | 1995-09-29 | 2002-11-27 | Biovitrum Ab | Conjugates of factor IX and a biocompatible polymer |
WO2003031464A2 (en) * | 2001-10-10 | 2003-04-17 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA00005376A (en) * | 1997-12-01 | 2002-07-02 | Neose Technologies Inc | Enzymatic synthesis of gangliosides. |
-
2004
- 2004-12-03 JP JP2006542888A patent/JP4738346B2/en not_active Expired - Fee Related
- 2004-12-03 EP EP04813394A patent/EP1694315A4/en not_active Withdrawn
- 2004-12-03 BR BRPI0417341-4A patent/BRPI0417341A/en not_active Application Discontinuation
- 2004-12-03 AU AU2004296860A patent/AU2004296860B2/en not_active Ceased
- 2004-12-03 CA CA002549413A patent/CA2549413A1/en not_active Abandoned
- 2004-12-03 WO PCT/US2004/041070 patent/WO2005055950A2/en active Application Filing
- 2004-12-03 MX MXPA06006023A patent/MXPA06006023A/en active IP Right Grant
- 2004-12-03 NZ NZ546733A patent/NZ546733A/en not_active IP Right Cessation
-
2006
- 2006-05-16 IL IL175661A patent/IL175661A0/en unknown
- 2006-05-30 KR KR1020067010603A patent/KR101209111B1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (en) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
EP1260582A1 (en) * | 1995-09-29 | 2002-11-27 | Biovitrum Ab | Conjugates of factor IX and a biocompatible polymer |
WO2003031464A2 (en) * | 2001-10-10 | 2003-04-17 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
Non-Patent Citations (1)
Title |
---|
DUDZIAK G ET AL: "Cyclodextrin-assisted Glycan Chain Extension on a Protected Glycosyl Amino Acid", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 32, 4 August 2000 (2000-08-04), pages 5865 - 5869, XP004229184, ISSN: 0040-4020 * |
Also Published As
Publication number | Publication date |
---|---|
AU2004296860B2 (en) | 2010-04-22 |
MXPA06006023A (en) | 2006-08-23 |
KR20060123224A (en) | 2006-12-01 |
AU2004296860A1 (en) | 2005-06-23 |
WO2005055950A3 (en) | 2005-10-20 |
CA2549413A1 (en) | 2005-06-23 |
NZ546733A (en) | 2009-07-31 |
JP2007513190A (en) | 2007-05-24 |
WO2005055950A2 (en) | 2005-06-23 |
JP4738346B2 (en) | 2011-08-03 |
EP1694315A2 (en) | 2006-08-30 |
IL175661A0 (en) | 2006-09-05 |
BRPI0417341A (en) | 2007-04-17 |
KR101209111B1 (en) | 2012-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175661A0 (en) | Glycopegylated factor ix | |
DE602004023400D1 (en) | Lies | |
IL175660A0 (en) | Glycopegylated erythropoietin | |
DE502004011703D1 (en) | N-heterocyclyl-phenylsubstituierte cyclische ketoenole | |
DE602004012071D1 (en) | T-hilfe | |
DE602004020356D1 (en) | Phenoxyessigsäurederivate | |
DE602004030538D1 (en) | Präzisionssubstratlagerbehälter | |
SG133617A1 (en) | General electric company | |
DE502004009243D1 (en) | Spirocyclische cyclohexan-derivate | |
AU155161S (en) | Case | |
DE602004027010D1 (en) | Thermotherapiehülle | |
DE502004003476D1 (en) | Standfuss | |
DE502004006683D1 (en) | Injection-locked-oscillator-schaltkreis | |
DE502004011852D1 (en) | Nspritzventil | |
DE502004004146D1 (en) | Pyrazolverbindungen | |
DE112004002769D2 (en) | Schienengeführtes transportsystem | |
DE60333037D1 (en) | Laser-radar | |
DK1665437T3 (en) | Reformeringsmodul | |
GB0311208D0 (en) | Feature based caricaturing | |
DE502004011343D1 (en) | Rotorspinnmaschine | |
DE602004012262D1 (en) | Benzimidazolonverbindung | |
EP1614695A4 (en) | Polypeptide | |
DE502004012153D1 (en) | Rotorspinnmaschine | |
DE10394343D2 (en) | Berührungslose biometrische erkennung | |
AU155596S (en) | Case |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060630 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20060731 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20060731 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEOSE TECHNOLOGIES, INC. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVO NORDISK A/S |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090924 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/48 20060101AFI20090918BHEP Ipc: C07K 14/745 20060101ALI20090918BHEP |
|
17Q | First examination report despatched |
Effective date: 20101029 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160502 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20160914 |